ABCT announces 2020 life sciences cohort
ABCT, the Accelerator for Biosciences in Connecticut, has announced the second cohort of emerging biosciences ventures invited to participate in its annual program.
The 2020 ABCT cohort participants and ventures include:
- Abhijit Patel (Yale): Binary Genomics aims to develop and commercialize a blood test to enable early cancer detection via tumor- derived DNA signatures in the circulation.
- Chad Bouton (Independent): Neuvotion technology treats those living with paralysis and movement disorders through AI-driven neurostimulation that modulates specific nerve and muscle targets to restore functional movement.
- David Rowe (UConn): Cloud based generation and analysis of biologically meaningful fluorescent histological signals from mineralized tissue to assess regenerative, therapeutic and genetic challenges affecting the skeletal system.
- Elizabeth Cusack (Independent): RBK Biotech has developed a nutritional product optimized for cancer care aimed at preventing and alleviating cancer related nutritional crisis and metabolically rooted treatment side effects.
- Henry Smilowitz (UConn): Iodine nanoparticles that enhance radiotherapy useful in better treating brain tumors and other cancers.
- Jayme Coates (Independent): Lactation Innovations Manoula is a non- invasive medical grade sensor that accurately detects the quantity of breast milk during breastfeeding to reduce prevalence of hypernatremic dehydration.
- Lawrence Silbart (Independent): Bandage Products LLC Therapeutic produces advanced wound care products using non-toxic biodegradable microneedles to ‘heal skin wounds and infections from the inside out.
- Mark Roser (Independent): Results Group has developed a passive ankle-foot exoskeleton that inserts a spring in parallel to the Achilles tendon to improve propulsion and plantar off-loading.
- Mrinal Kumar (Independent): OnTrack Rehabilitation stimulates patient balance and vision to drive faster, safer, concussion recovery.
- Triantafyllos Tafas (Independent): QCDx develops a novel liquid biopsy to deliver precision cancer diagnosis via early cancer detection, monitoring of treatment efficacy, and surveillance for disease recurrence.
- Thomas Wilson (Independent): Interact Medical delivering the clinical benefits of patient-matched implants and innovative 3D- printable materials to more patients through a focused, expedited service.
- Yaw Ofuso Ansong Jr. (University of New Haven): Kova is building an AI-backed medical diagnostic platform that makes the diagnosis of sickle cell and other blood diseases cheaper, on-demand and more efficient. more